Bright Angel Therapeutics and Schrödinger, Inc. entered into a collaboration in late 2017 whereby Schrödinger leverages its state of the art in-silico drug development platforms in up to three joint programs to design and develop fungal selective compounds. Fungal selectivity is critical in the development of new antifungal drugs as fungi and human are both eukaryotes and share many of the same essential biological processes.